Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study

Table 1

Baseline demographic and clinical characteristics of the patients (n=498).

Characteristic	TACE+sorafenib; (n=69)	TACE; (n=429)	X^2/t/z; Value	P Value
Age	51 (21-79)	51 (18-84)	-0.431	0.667
Sex
Male	59	380	0.537	0.464
Female	10	49
Child-Pugh
A	67	406	0.756	0.385
B	2	23
AFP	12307.24±20255.88	19716.23±25103.12	-2.117	0.034
Number
<3	58	368	0	0.985
≥3	11	68
Size	8.39±4.45	9.65±3.25	-2.020	0.043
Type
I/II	43	182	9.499	0.002
III/IV	26	247
Treatment after TACE
surgery	1	5	0.014	0.993
RFA	1	6
radiotherapy	2	11

p<0.05